About US
Contact us
-
Endo whistleblower nabs $33.6M from feds for 'extraordinary' work in FCA suitFormer Endosales rep Peggy Ryan first filed a whistleblower suit--concerning off-label marketing of its pain patch, Lidoderm--against the drugmaker in 2005. Nine years later, the company settled with2015/7/17
-
UPDATED: Lilly's Alimta gets rating boost in update to ASCO's drug scorecardWhen theAmerican Society of Clinical Oncologyunveiled its scheme for assessing the value of cancer drugs, it included some less-than-flattering drug ratings. One of those was for Eli Lilly's ($LLY)Ali2015/7/16
-
'Modern Family' star signs on with BMS for immuno-oncology awarenessPharma-watchers may be very familiar with immuno-oncology, what with two hot new cancer drugs already making waves and plenty of others still in the pipeline following behind them. But the average Ame2015/7/16
-
CFDA Minister Bi Jingquan meets French Ambassador to ChinaOn the afternoon of July 13, 2015, Bi Jingquan, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Mr. Maurice Gourdault-Montagne, the French Ambassador to China. Bo2015/7/15
-
FDA slaps Emcure with import alert, adding to ban on Indian plantsTheFDAhas banned yet another Indian drug plant. An import alert for all human and animal drugs from an Emcure Pharmaceuticals plant in Hinjawadi, with a few exceptions, was issued on Monday, according2015/7/15
-
Playing catch-up on Big Biotech goal, Shire broadens M&A focusShire's ($SHPG) $54 billion tie-up with AbbVie ($ABBV)--and the subsequent cancellation of that deal--shook up employees and stalled CEOFlemming Ornskov's plans to transform the company into a biotech2015/7/15
-
House passes 21st Century Cures billMembers of U.S. House of Representatives voted 344 to 77 today to approve the 21st Century Cures bill. It now goes to the Senate for consideration. Supporters like it because it provides more funds fo2015/7/13
-
Novartis' pay-for-performance Entresto plan has its critics--Express Scripts' Miller among themNovartis ($NVS) has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the plan--and the CMO at leading PB2015/7/13
-
CFDA issues Measures for Unannounced Inspection of Drugs and Medical DevicesChina Food and Drug Administration (CFDA) recently issued the Measures for Unannounced Inspection of Drugs and Medical Devices, which will be implemented as of September 1, 2015. The Measures comprise2015/7/10
-
Glaxo's HIV unit ViiV aims to steal share from Gilead before patents biteGlaxoSmithKline's ($GSK)ViiV Healthcarestole the show in Q1, surpassing analyst expectations and prompting the pharma to hang on to theHIVdrug business, canceling all plans for a potential spinoff. Th2015/7/10